Cargando…

Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure

The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Nieto-Garai, Jon Ander, Glass, Bärbel, Bunn, Carmen, Giese, Matthias, Jennings, Gary, Brankatschk, Beate, Agarwal, Sameer, Börner, Kathleen, Contreras, F. Xabier, Knölker, Hans-Joachim, Zankl, Claudia, Simons, Kai, Schroeder, Cornelia, Lorizate, Maier, Kräusslich, Hans-Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131562/
https://www.ncbi.nlm.nih.gov/pubmed/30233582
http://dx.doi.org/10.3389/fimmu.2018.01983
_version_ 1783354132500840448
author Nieto-Garai, Jon Ander
Glass, Bärbel
Bunn, Carmen
Giese, Matthias
Jennings, Gary
Brankatschk, Beate
Agarwal, Sameer
Börner, Kathleen
Contreras, F. Xabier
Knölker, Hans-Joachim
Zankl, Claudia
Simons, Kai
Schroeder, Cornelia
Lorizate, Maier
Kräusslich, Hans-Georg
author_facet Nieto-Garai, Jon Ander
Glass, Bärbel
Bunn, Carmen
Giese, Matthias
Jennings, Gary
Brankatschk, Beate
Agarwal, Sameer
Börner, Kathleen
Contreras, F. Xabier
Knölker, Hans-Joachim
Zankl, Claudia
Simons, Kai
Schroeder, Cornelia
Lorizate, Maier
Kräusslich, Hans-Georg
author_sort Nieto-Garai, Jon Ander
collection PubMed
description The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development.
format Online
Article
Text
id pubmed-6131562
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61315622018-09-19 Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure Nieto-Garai, Jon Ander Glass, Bärbel Bunn, Carmen Giese, Matthias Jennings, Gary Brankatschk, Beate Agarwal, Sameer Börner, Kathleen Contreras, F. Xabier Knölker, Hans-Joachim Zankl, Claudia Simons, Kai Schroeder, Cornelia Lorizate, Maier Kräusslich, Hans-Georg Front Immunol Immunology The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development. Frontiers Media S.A. 2018-09-04 /pmc/articles/PMC6131562/ /pubmed/30233582 http://dx.doi.org/10.3389/fimmu.2018.01983 Text en Copyright © 2018 Nieto-Garai, Glass, Bunn, Giese, Jennings, Brankatschk, Agarwal, Börner, Contreras, Knölker, Zankl, Simons, Schroeder, Lorizate and Kräusslich. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nieto-Garai, Jon Ander
Glass, Bärbel
Bunn, Carmen
Giese, Matthias
Jennings, Gary
Brankatschk, Beate
Agarwal, Sameer
Börner, Kathleen
Contreras, F. Xabier
Knölker, Hans-Joachim
Zankl, Claudia
Simons, Kai
Schroeder, Cornelia
Lorizate, Maier
Kräusslich, Hans-Georg
Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_full Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_fullStr Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_full_unstemmed Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_short Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure
title_sort lipidomimetic compounds act as hiv-1 entry inhibitors by altering viral membrane structure
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131562/
https://www.ncbi.nlm.nih.gov/pubmed/30233582
http://dx.doi.org/10.3389/fimmu.2018.01983
work_keys_str_mv AT nietogaraijonander lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT glassbarbel lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT bunncarmen lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT giesematthias lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT jenningsgary lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT brankatschkbeate lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT agarwalsameer lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT bornerkathleen lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT contrerasfxabier lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT knolkerhansjoachim lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT zanklclaudia lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT simonskai lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT schroedercornelia lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT lorizatemaier lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure
AT krausslichhansgeorg lipidomimeticcompoundsactashiv1entryinhibitorsbyalteringviralmembranestructure